Pharmaceutical developer ImaRx Therapeutics said the first patient has been treated in a new phase II clinical trial evaluating the safety and effectiveness of its SonoLysis product for the treatment of acute ischemic stroke.
SonoLysis combines external ultrasound and ImaRx's proprietary nanobubble technology to clear blood clots. The evaluation is a multicenter randomized and blinded trial with 40 patients, according to the Tucson, AZ-based firm.
By AuntMinnie.com staff writers
April 5, 2005
Related Reading
ImaRx raises $7 million, March 10, 2005
ImaRx, Guerbet in MR molecular imaging deal, December 10, 2004
ImaRx completes private placement, names chairman, April 2, 2004
ImaRx inks licensing deal, November 19, 2003
Clinical trials begin for ImaRx, September 18, 2003
Copyright © 2005 AuntMinnie.com